Click on image to view larger version.

Figure 2 LDL lowering in primary and secondary prevention trials of statin therapy. The mean LDL enrollment levels are depicted for major trials testing statin utility in primary prevention (WOSCOPS, AFCAPS) and secondary prevention (4S, CARE, LIPID) of coronary artery disease. Mean LDL levels achieved after statin therapy in each trial are also depicted. The NCEP-recommended goals for LDL lowering are depicted for both primary and secondary CAD prevention. Note that mean LDL levels achieved with statins in the AFCAPS primary prevention trial to determine drug efficacy are lower than the NCEP goals. (*Absolute value extrapolated from a reported 25% reduction in LDL [23]).